Veracyte Inc Equity-NMS: VCYT

Healthcare

Diagnostics & Research

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$43.78
Open :	$42.35
Today's high :	$42.56
Today's low :	$40.5
52W low :	$18.61
52W high :	$46
1Y :	55.87%
5Y :	46.56%
EPS(TTM): :	-0.13
Shares O/S :	77.5 M
Market cap :	3.22 B

What is the share price of Veracyte Inc today?

Veracyte Inc (VCYT) share price as of January 11, 2025, is $41.58. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Veracyte Inc?

Yes, Indian Investors can invest in the Veracyte Inc (VCYT) Share by opening an international trading account with Angel One.

How can I purchase Veracyte Inc shares in India?

Purchasing Veracyte Inc (VCYT) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Veracyte Inc (VCYT) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Veracyte Inc?

Yes, you can purchase fractional shares of Veracyte Inc (VCYT) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Veracyte Inc?

The market capitalization of Veracyte Inc on January 11, 2025, is $3.22 B.

In which sector Veracyte Inc belongs?

Veracyte Inc operates in the Healthcare sector, specifically in the Diagnostics & Research industry.

What documents are required to invest in Veracyte Inc stocks?

In order to invest in Veracyte Inc (VCYT) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.